2010 Australian federal budget

Proactive news headlines including Poseidon Nickel, Krakatoa Resources, Brookside Energy and Nova Minerals

Retrieved on: 
Monday, November 21, 2022
Poseidon, Well, TPD, 2010 Australian federal budget, Health, ADN, AOI, Black Swan Project, BSX, DUN, NED, Gold, Mineral, Research, KTA, Carbon, BFS, Nickel, HHI, REE, CSG, Great, OTC, Carnage, Lachlan Fold Belt, ASX, CPH, Case Western Reserve University, CWRU, Tower, DSF Refractories & Minerals Ltd, MRE, MSV, Whiteness Project, AVL, Copper, SHP, MGV, NVA, R, US, POS, OTCQB, BRU, PGE, IMCD, White, GTM, OTCQX, Proactivity, Sale, RC, Hydrogen, Tiwi, VMS, Rare-earth element, Oil, Renewable energy, Uranium, Mining, NSW

Click here

Key Points: 
  • Click here
    Nova Minerals Ltd (ASX:NVA, OTCQB:NVAAF) has received firm commitments for a placement to raise A$30 million (US$20 million) at A$0.70 per share.
  • Click here
    Talon Energy Ltd (ASX:TPD) welcomes the progress being made by partner TMK Energy Ltd at the Gurvantes XXXV CSG Project in the South Gobi Basin in Mongolia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Immutep Receives Australian R&D Tax Incentive

Retrieved on: 
Monday, November 14, 2022
Immunotherapy, Trial of the century, R, CIR, Calendar, AusIndustry, Immutep, Autoimmune disease, 2010 Australian federal budget, US, Cancer, APC, LAG-3, Research, Union, ASX, IMM, Patient, Antibody, Pharmaceutical industry

SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2021 fiscal year, mainly related to the Company’s TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Key Points: 
  • SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Governments R&D tax incentive program.
  • Due to the Advance Finding, both Immuteps Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive.
  • As previously announced, in September 2022, Immutep also received the French CIR tax incentive of 1,804,341 (~ US$1,862,143) through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union during the 2021 calendar year.
  • Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti.

Vaxxas receives $8.2 million grant to support manufacturing scale-up in its Australian manufacturing facility

Retrieved on: 
Tuesday, September 20, 2022
Health, Health Technology, Other Health, General Health, Pharmaceutical, Biotechnology, Workforce, Federal, Efficiency, Federation, Department, Foodservice, Food, Refrigeration, Medicine, Vaccination, Population, Growth, MMI, Eye, Vaccine, University, Transport, 2010 Australian federal budget, Biotechnology, Department of Industry, Science and Resources, Skin, Pharmaceutical industry, Science, Space, Defense

The Brisbane production facility will support late-stage clinical trials and early commercial production.

Key Points: 
  • The Brisbane production facility will support late-stage clinical trials and early commercial production.
  • We are incredibly grateful to the Australian Federal Government for their ongoing support of our vaccination technology, Vaxxas Chief Executive Officer David Hoey said.
  • With support from the Queensland State Government, the Vaxxas Biomedical Facility is being constructed in Northshore, Brisbane and due to open in early 2023.
  • Vaxxas will work with the Department of Industry, Science and Resources over the coming weeks to finalise grant details.

The Electric Future of Lithium as it Aims to Meet the Global EV Demand

Retrieved on: 
Friday, September 2, 2022
Lithium, Crypto, PGE, CEO, Mining, Carbon, Mercedes-Benz, Climate change, Federation, Miller, Disclosure, Move, Company, Project, Risk, Inflation, GEMS, Sale, LCT, Board, Renewable energy, IR, Metal, Gold, Patriot, OTC Markets Group, Green Revolution, Development, Social media, Partnership, RC, Bloomberg, Ownership, Publishing, Infinity Stones, Finnis, Corvette, Core electron, Water, FCI, News, ASX, Molybdenum, EVS, Growth, AI, Marketing, CSE, Policy, IOT, Silver, Cree, Play, Cannabis, Interview, EV, Clean technology, Tesla, Copper, 2010 Australian federal budget, Car dealership, Core, Delta

Read the full article on Investorideas.com:

Key Points: 
  • Read the full article on Investorideas.com:
    As more countries push forward with their green energy initiatives, the EV sector is driving growth for new lithium mining developments.
  • In recent news , "The global lithium-ion battery market is expected to grow by a factor of five to 10 in the next decade .
  • Reaching aggressive targets for electric vehicles (EVs) and battery-based energy storage system production relies on materials such as lithium and rare earth metals.
  • Joe Lowry of Global Lithium doesn't expect future lithium supplies to keep up with demand.

Microba Completes Successful IPO

Retrieved on: 
Tuesday, April 5, 2022
Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, Company, Therapy, 2010 Australian federal budget, Ginkgo, USD, DNA, Synthetic biology, Growth, University, NYSE, Board, Data bank, Research, Health, MAP, Intelligence, View, ASX, Australian Securities Exchange, Technology, Cervical cancer, Data, Inflammatory bowel disease, IPO, Disease, Antibiotics, Public relations, Pharmaceutical industry, Illumina, EU, G42

Microba Life Sciences Limited (ASX: MAP) (Microba or the Company) is an Australian-based commercial stage company with leading technology for measuring the human gut microbiome.

Key Points: 
  • Microba Life Sciences Limited (ASX: MAP) (Microba or the Company) is an Australian-based commercial stage company with leading technology for measuring the human gut microbiome.
  • NYSE listed synthetic biology company Ginkgo Bioworks1 (NYSE: DNA) invested USD $3.5m into Microba IPO, becoming a ~4% shareholder of the Company.
  • Microba will have a positive impact on human lives globally when we are successful in achieving our goals.
  • Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, automic group.

GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 11, 2021
Financial management, Securities Exchange Act of 1934, Harvard University, Acceleration, ID, Architect, National, Security, Patient, University, University of Newcastle, Diabetes, IRB, Conference, GLOBE, Company, Financial stability, Nasdaq, Private Securities Litigation Reform Act, GBS, Terminology, Security (finance), International, 2010 Australian federal budget, IPO, U.S. Securities and Exchange Commission, Technology, Webcast, Marketing, Securities Act of 1933, Calendar, Wyss Institute, Forward-looking statement, Johns Hopkins University, Twitter, LinkedIn, Federation, Government, NEW, Cryptocurrency, Medical device, Pharmaceutical industry, Risk management

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results for the fourth financial quarter and full-year ended June 30, 2021, and provided a recent business update. Management will host a webcast and conference call at 4:30 p.m. today after market.

Key Points: 
  • This has been a tremendous year for GBS marked by advances in our regulatory affairs, IRB approval to commence clinical studies, strategic partnerships and financial management.
  • We have made great progress towards commercializing our novel saliva-glucose test and the opportunities to expand our pipeline are very exciting.
  • Most recently, a grant from the Australian Federal Government to financially support our next-generation high-tech manufacturing facility highlights the confidence others see in our technology and approach.
  • With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes.